CN1718588A - 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断方法、诊断试剂盒及其应用 - Google Patents
抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断方法、诊断试剂盒及其应用 Download PDFInfo
- Publication number
- CN1718588A CN1718588A CN 200410040919 CN200410040919A CN1718588A CN 1718588 A CN1718588 A CN 1718588A CN 200410040919 CN200410040919 CN 200410040919 CN 200410040919 A CN200410040919 A CN 200410040919A CN 1718588 A CN1718588 A CN 1718588A
- Authority
- CN
- China
- Prior art keywords
- hla
- antibody
- cancer
- monoclonal antibody
- cell strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010024164 HLA-G Antigens Proteins 0.000 title claims abstract description 161
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 title claims abstract description 140
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 79
- 201000011510 cancer Diseases 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 41
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 4
- 238000003745 diagnosis Methods 0.000 title description 11
- 210000004881 tumor cell Anatomy 0.000 title description 6
- 230000003248 secreting effect Effects 0.000 title 1
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 29
- 238000006243 chemical reaction Methods 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 65
- 239000000427 antigen Substances 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 230000036039 immunity Effects 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 16
- 238000004393 prognosis Methods 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 11
- 230000001900 immune effect Effects 0.000 claims description 10
- 230000003211 malignant effect Effects 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 238000003149 assay kit Methods 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 230000002055 immunohistochemical effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 47
- 210000001519 tissue Anatomy 0.000 description 39
- 206010006187 Breast cancer Diseases 0.000 description 25
- 208000026310 Breast neoplasm Diseases 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000011160 research Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 230000001744 histochemical effect Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 210000005075 mammary gland Anatomy 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 206010016629 fibroma Diseases 0.000 description 6
- 238000012151 immunohistochemical method Methods 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 206010000234 Abortion spontaneous Diseases 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 208000015994 miscarriage Diseases 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 210000005059 placental tissue Anatomy 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000000995 spontaneous abortion Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000002993 trophoblast Anatomy 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 208000012991 uterine carcinoma Diseases 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 101150024418 HLA-G gene Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000005092 tracheal tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Abstract
Description
化合物 | 交叉反应% |
HLA-GHLA-A2HLA-B4HLA-C混合白细胞 | 1000.010.010.0010.005 |
HLA-G表达 | ||||||
例数 | 阴性 | + | ++ | +++ | 阳性% | |
结肠-直肠癌 | 200 | 70 | 66 | 39 | 25 | 64.7 |
胃癌 | 101 | 37 | 32 | 19 | 13 | 62.7 |
食道癌 | 61 | 10 | 19 | 16 | 16 | 83.6 |
肝胆癌 | 6 | 2 | 2 | 1 | 1 | 66.7 |
肺癌 | 42 | 14 | 9 | 10 | 9 | 66.6 |
乳腺癌 | 178 | 59 | 55 | 35 | 29 | 66.8 |
子宫癌 | 70 | 23 | 18 | 24 | 5 | 67.1 |
子宫颈癌 | 41 | 24 | 9 | 5 | 3 | 41.5 |
卵巢癌 | 30 | 16 | 7 | 5 | 2 | 46.7 |
前列腺癌 | 31 | 14 | 8 | 5 | 4 | 54.8 |
睾丸癌 | 6 | 3 | 2 | 1 | 0 | 50.0 |
肾癌 | 10 | 5 | 1 | 1 | 3 | 50.0 |
膀胱癌 | 36 | 13 | 11 | 8 | 4 | 63.9 |
甲状腺癌 | 5 | 1 | 2 | 1 | 1 | 80.0 |
喉癌 | 18 | 1 | 9 | 3 | 5 | 94.4 |
良性肿瘤 | 172 | 172 | 0 | 0 | 0 | 0 |
HLA-G表达阳性 | 临床意义 | |
乳腺癌 | 癌转移54.4%癌症高检出率(78.2%比医学影像法检出率高25.8%) | 预后不良诊断准确率高 |
食道癌 | 癌转移/细胞异化60..9%癌症高检出率(83.6%)医学影像法检出率为66% | 预后不良诊断准确率高 |
胃癌 | 癌转移71.9% | 预后不良 |
直肠-结肠癌 | 癌转移/细胞异化/浸润67%癌症高检出率(64.7%比医学影像法检出率高18%) | 预后不良诊断准确率高 |
肺癌 | 癌转移/细胞异化78.5%高病理分期 | 预后不良 |
子宫癌 | 癌转移/细胞异化75%高病理分期 | 预后不良 |
膀胱癌 | 高病理分期 | 预后不良 |
喉癌 | 癌症高检出率(94.4%比医学影像法检出率高55%) | 诊断准确率高 |
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410040919XA CN1312182C (zh) | 2004-10-26 | 2004-10-26 | 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410040919XA CN1312182C (zh) | 2004-10-26 | 2004-10-26 | 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1718588A true CN1718588A (zh) | 2006-01-11 |
CN1312182C CN1312182C (zh) | 2007-04-25 |
Family
ID=35930547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410040919XA Expired - Fee Related CN1312182C (zh) | 2004-10-26 | 2004-10-26 | 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1312182C (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101358964B (zh) * | 2007-07-31 | 2012-06-20 | 叶尚勉 | 含抗hla-g的单克隆抗体的癌症诊断试剂盒及其应用 |
CN102574905A (zh) * | 2009-06-18 | 2012-07-11 | Hla-G科技公司 | HLA-Gα1多聚体及其药学用途 |
CN103756967A (zh) * | 2013-12-31 | 2014-04-30 | 卢英 | 抗hla-g的单克隆抗体偶联免疫磁珠在肿瘤细胞分选中的应用 |
US9632086B2 (en) | 2011-12-31 | 2017-04-25 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Method and kit for determining-antibody sensitivity and clone cell strain |
CN107533051A (zh) * | 2015-03-27 | 2018-01-02 | 南加利福尼亚大学 | Hla‑g作为car t细胞免疫疗法的新靶标 |
CN109563169A (zh) * | 2016-06-03 | 2019-04-02 | 英韦克泰斯公司 | 抗hla-g特异性抗体 |
CN109952318A (zh) * | 2016-11-18 | 2019-06-28 | 豪夫迈·罗氏有限公司 | 抗hla-g抗体及其用途 |
EP2917229B1 (en) | 2012-11-12 | 2020-01-08 | Invectys | Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof |
CN112794908A (zh) * | 2020-12-31 | 2021-05-14 | 杭州冰湖生物科技有限公司 | 一种抗hla-g抗体的制备及分析方法 |
CN113045656A (zh) * | 2020-07-27 | 2021-06-29 | 台州恩泽医疗中心(集团) | 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
US11208487B2 (en) | 2018-09-27 | 2021-12-28 | Tizona Therapeutics | Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies |
CN114605543A (zh) * | 2021-12-17 | 2022-06-10 | 台州恩泽医疗中心(集团) | 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
WO2023184733A1 (zh) * | 2022-03-31 | 2023-10-05 | 台州恩泽医疗中心(集团) | 一种抗hla-g分子的单克隆抗体及其用途 |
US11981737B2 (en) | 2016-11-18 | 2024-05-14 | Hoffmann-La Roche Inc. | Anti-HLA-G antibodies and use thereof |
-
2004
- 2004-10-26 CN CNB200410040919XA patent/CN1312182C/zh not_active Expired - Fee Related
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101358964B (zh) * | 2007-07-31 | 2012-06-20 | 叶尚勉 | 含抗hla-g的单克隆抗体的癌症诊断试剂盒及其应用 |
CN102574905A (zh) * | 2009-06-18 | 2012-07-11 | Hla-G科技公司 | HLA-Gα1多聚体及其药学用途 |
US9632086B2 (en) | 2011-12-31 | 2017-04-25 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Method and kit for determining-antibody sensitivity and clone cell strain |
EP2917229B1 (en) | 2012-11-12 | 2020-01-08 | Invectys | Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof |
CN103756967A (zh) * | 2013-12-31 | 2014-04-30 | 卢英 | 抗hla-g的单克隆抗体偶联免疫磁珠在肿瘤细胞分选中的应用 |
CN103756967B (zh) * | 2013-12-31 | 2018-09-21 | 卢英 | 抗hla-g的单克隆抗体偶联免疫磁珠在肿瘤细胞分选中的应用 |
CN107533051A (zh) * | 2015-03-27 | 2018-01-02 | 南加利福尼亚大学 | Hla‑g作为car t细胞免疫疗法的新靶标 |
CN109563169B (zh) * | 2016-06-03 | 2022-07-01 | 英韦克泰斯公司 | 抗hla-g特异性抗体 |
CN109563169A (zh) * | 2016-06-03 | 2019-04-02 | 英韦克泰斯公司 | 抗hla-g特异性抗体 |
US11634494B2 (en) | 2016-06-03 | 2023-04-25 | Invectys SA | Anti HLA-G specific antibodies |
US11312774B2 (en) | 2016-06-03 | 2022-04-26 | Invectys SA | Anti HLA-G specific antibodies |
US11981737B2 (en) | 2016-11-18 | 2024-05-14 | Hoffmann-La Roche Inc. | Anti-HLA-G antibodies and use thereof |
CN109952318A (zh) * | 2016-11-18 | 2019-06-28 | 豪夫迈·罗氏有限公司 | 抗hla-g抗体及其用途 |
CN109952318B (zh) * | 2016-11-18 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 抗hla-g抗体及其用途 |
US11208487B2 (en) | 2018-09-27 | 2021-12-28 | Tizona Therapeutics | Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies |
CN113045656B (zh) * | 2020-07-27 | 2022-03-08 | 台州恩泽医疗中心(集团) | 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
CN113045656A (zh) * | 2020-07-27 | 2021-06-29 | 台州恩泽医疗中心(集团) | 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
CN112794908A (zh) * | 2020-12-31 | 2021-05-14 | 杭州冰湖生物科技有限公司 | 一种抗hla-g抗体的制备及分析方法 |
CN114605543A (zh) * | 2021-12-17 | 2022-06-10 | 台州恩泽医疗中心(集团) | 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
CN114605543B (zh) * | 2021-12-17 | 2023-11-07 | 台州恩泽医疗中心(集团) | 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
WO2023184733A1 (zh) * | 2022-03-31 | 2023-10-05 | 台州恩泽医疗中心(集团) | 一种抗hla-g分子的单克隆抗体及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1312182C (zh) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hishima et al. | CD5 expression in thymic carcinoma. | |
Vitale et al. | HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions | |
CN1283652C (zh) | 分离的编码癌相关抗原的核酸分子和该抗原本身及它们的用途 | |
CN101460630B (zh) | He4与其它生化标记物在卵巢癌评估中的应用 | |
CN1718588A (zh) | 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断方法、诊断试剂盒及其应用 | |
RU2451521C2 (ru) | Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их | |
CN1662254A (zh) | Alcam和alcam调制剂 | |
CN1653336A (zh) | 肝细胞癌的诊断 | |
JPS60202898A (ja) | ヒトの卵巣ガンと子宮ガンに対するモノクロ−ナル抗体 | |
BRPI0909672B1 (pt) | método de imunoensaio in vitro para detecção da presença de células de câncer de fígado em um indivíduo, método para classificação de células de câncer de fígado presentes em um indivíduo, método in vitro para determinação de administrar ou não um agente anticâncer contendo um anticorpo anti-glipicano 3 a um indivíduo, e método in vitro para determinação de uma dose de um agente anticâncer contendo um anticorpo anti-glipicano 3 no tratamento de câncer de fígado em um indivíduo | |
EP2054443B1 (en) | Antibodies to an epitope of agr2, assays and hybridomas | |
CN100384875C (zh) | 蛋白质 | |
EP1536006A1 (en) | Cancer antigens and utilization thereof | |
CN1160369C (zh) | 抗细胞质胸苷激酶-IgY抗体的制备及肿瘤诊断组合物 | |
CN1296711C (zh) | 乳腺癌的Her-2免疫组织化学诊断试剂盒 | |
EP2204448B1 (en) | Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer | |
Hellström et al. | Tumor antigens | |
Ramaekers et al. | Keratins as differentiation markers in tumor biology and surgical pathology | |
CN1766634A (zh) | 一种检测乳腺球蛋白的方法及其试剂盒 | |
KR101777254B1 (ko) | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
CN1328567A (zh) | 乳房珠蛋白,一种分泌性乳房特异性乳腺癌蛋白 | |
CN103429617A (zh) | 包含抗-ck8/18复合物自身抗体的标记物及其诊断癌症的用途 | |
CN1295668A (zh) | 用于肝细胞癌诊断的方法和组合物 | |
JPH04502363A (ja) | 癌及びその他の疾病の診断としての基底膜成分の検出 | |
CN100491527C (zh) | 特征在于检测g-csf外显子3缺失的癌症诊断方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20081224 |
|
ASS | Succession or assignment of patent right |
Owner name: SICHUAN SHOUCHUANG BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SICHUAN XINCHUANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO. LTD. Effective date: 20130604 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 611130 CHENGDU, SICHUAN PROVINCE TO: 641300 ZIYANG, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130604 Address after: 641300, Yanjiang seven, Sichuan City, East Ziyang New District biomedical science and Technology Industrial Park, latitude road Patentee after: Sichuan first biological pharmaceutical Co., Ltd. Address before: 611130, Sichuan, Chengdu, Chengdu science and Technology Industrial Development Center on both sides of the Taiwan Strait innovation center, building 12 Patentee before: Sichuan Xinchuang Biological Science and Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070425 Termination date: 20161026 |
|
CF01 | Termination of patent right due to non-payment of annual fee |